USAN drug names under consideration

Updated | 3 Min Read

USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.

Visit United States Adopted Names FAQ to learn more.

Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected]. 

In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following names for the drugs described are "under consideration" by the USAN Council:

October 2026

Cimlespagene parvec: Treatment of Spastic Paraplegia Type 50 (SPG50)

Delpacibart zotadirsen: Treatment of muscular dystrophy diseases

Ferucadextran: MRI Contrast Agent

Inatovtabart: Antineoplastic, treatment of advanced or metastatic urothelial carcinoma

Izovocabgene geleucel: Treatment of autoimmune disorders

Lumonistrocel: Treatment of spinocerebellar degeneration (SCD), also called spinocerebellar ataxia (SCA)

Nelvutamig: Treatment of advanced solid tumors

Nenocorilant: Treatment of solid tumors

Pabinafusp alfa: Mucopolysaccharidosis type II (MPS II, Hunter Syndrome)

Reltodecacog alfa: Restoring coagulation by bypassing factor Xa inhibitor-mediated anticoagulation

Silmoretgene parvec: Treatment of AIPL1-related inherited retinal dystrophy (AIPL1-IRD)

Simgotindeg: Antineoplastic, treatment of solid tumors

Tifeglipron: Glycemia control and weight loss in overweight and obese patients

Zacamecgene parvec: Treatment of Rett syndrome

Zaloganan: Treatment of periprosthetic joint infection (PJI)

Zaloganan acetate: Treatment of periprosthetic joint infection (PJI)

Zareprumig: Treatment of multiple sclerosis (MS)

September 2026

Asedebart: Treatment of conditions characterized by chronically elevated adrenocorticotropic hormone (ACTH)

Copper Cu 64 Abefolastat Tesaroxetan: Diagnostic agent, oncology

Dalretapopt: Treatment of advanced solid tumors harboring TP53 Y220C mutation

Dipalmitoyl hydroxyproline: Treatment of Netherton Syndrome (NS)

Duvobotgene erpavec: Gene therapy for the treatment of urinary incontinence

Felcorekibart: Treatment of adult and pediatric patients aged 12 years and older with asthma

Filimelnotide: Treatment of rare genetic, syndromic, and acquired diseases of obesity such as hypothalamic obesity (HO), and other obesities caused by deficiencies within the MC4R pathway

Filimelnotide hydrochloride: Treatment of rare genetic, syndromic, and acquired diseases of obesity such as hypothalamic obesity (HO), and other obesities caused by deficiencies within the MC4R pathway           

Mocertatug rezetecan: Antineoplastic

Grebenpepimut simolenin alfa: Treatment of cancer

Grivamisulpride: Treatment of schizophrenia

Insulin eftuxvet: Treatment of feline (cat) diabetes

Melurotogene parvec: Treatment of OTOF-related congenital hearing loss

Pinverasib: Antineoplastic

Rezetecan: Treatment of advanced solid tumors

Sunakiment: Treatment of asthma and obstructive airway diseases

Tanerasertib: Antineoplastic, treatment of advanced solid tumors with the AKT1 E17K mutation

Tanerasertib maleate:  Antineoplastic, treatment of advanced solid tumors with the AKT1 E17K mutation

Tegacorat: Treatment of inflammatory diseases

Tirgadisgene parvec: Treatment of Duchenne muscular dystrophy (DMD) in patients with confirmed mutations in the dystrophin gene

Ubletamig: Antineoplastic, treatment of ovarian cancer and MUC16-expressing cancers

Umiposgene parvec: Treatment of heart failure (HF)

August 2026

Adimanebart: Treatment of neuromuscular diseases with impaired neuromuscular junction (NMJ) function

Arumakimig: Anti-inflammatory

Claseprubart: Treatment disorders driven by the complement pathway (CP) cascade

Cleminorexton: Treatment of narcolepsy

Emrusolmin: Treatment of multiple system atrophy (MSA)

Mirivadelgat: Treatment of Fanconi anemia (FA) 

Mirivadelgat hydrochloride: Treatment of Fanconi anemia (FA) 

Mocertatug: Antineoplastic

Mocertatug rezetecan: Antineoplastic

Nucresiran: Treatment of transthyretin (TTR)-mediated amyloidosis (ATTR Amyloidosis) 

Nucresiran sodium: Treatment of transthyretin (TTR)-mediated amyloidosis (ATTR Amyloidosis)   

Pilabactam: Treatment of complicated urinary tract infections (cUTI), hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated intraabdominal infections (cIAI) 

Pimurutamab: Treatment of advanced solid tumors

Risvutatug: Antineoplastic  

Risvutatug rezetecan:

Utreglutide: Treatment of Type II diabetes in obese or overweight patients with comorbidities

Velzatinib: Treatment of unresectable and/or metastatic gastrointestinal stromal tumors    

Vormatrigine: Treatment of adult focal onset epilepsy

Zilovertamab vedotin: Antineoplastic

Zolucatetide: Treatment of advanced and/or metastatic solid tumors

FEATURED STORIES

Man power walking or jogging, with dumbbells

New changes expand diabetes-prevention for more Medicare patients

| 3 Min Read
Three healthcare workers in discussion

AMA Joy in Medicine points the way to better care

| 5 Min Read
Doctors hold up magnifying glasses over a giant pancreas

Beyond watch and wait: Taking aim at pancreatic cysts

| 7 Min Read
Philip Kuriakose, MD, featured on "Health vs. Hype" AMA podcast

5 things patients should know about microplastics

| 8 Min Read